Lymphoid Malignancy Flashcards

(37 cards)

1
Q

Lymphoma

A

A cancer of lymphoid origin. This can present with enlarged lymph nodes, extranodal involvement or bone marrow involvement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Systemic B Symptoms

A

Weight loss (> 10% in 6 months), fever, night sweats, pruritus, fatigue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How is the classification of lymphoma decided

A

Biopsy of site of tumour

Clinical examination and imaging (CT) tell us where it is.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Science of lymphoma

A

Malignancy occurs in the lymphoid region (germinal centre). To the lymph glands and the secondary lymphoid tissue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lymphoproliferative Disorders

A

Acute lymphoblastic leukaemia (ALL)
Chronic lymphocytic leukaemia (CLL)
Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Most common lymphoproliferative disorder

A

Non-hodgkin Lymphoma (High grade diffuse large B-cell lymphoma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Acute Lymphoblastic Leukaemia

A

Neoplastic disorder of lymphoblasts diagnosed by >20% lymphoblasts present in the bone marrow.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Epidemiology of ALL

A

Incidence 1-2/100,000 population/year
75% cases occur in children < 6 years
75-90% cases are of B-cell lineage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Presentation of ALL

A

2-3 week history of bone marrow failure (with possible raised white cell count) or bone and joint pain, infection, night sweats

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Emergency treatment in every lymphoma

A

Steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Standard treatment of ALL

A

Induction chemotherapy to obtain remission

Consolidation therapy

CNS directed treatment

Maintenance treatment for 18 months

Stem cell transplantation if they are high risk (20-30% mortality)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Indicators of poor prognosis in ALL

A

Increasing age

Increased white cell count

Immunophenotype (more primitive forms)

Cytogenetics/molecular genetics t(9,22), t(3;11)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Adult outcome ALL

A

complete remission rate 78–91%

leukaemia-free survival at 5y 30–35%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Child outcome ALL

A

5y overall survival ~90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Chronic Lymphocytic Leukaemia

A

Diagnosed by blood >5x10^9/L lymphocytes.
Bone marrow >30% lymphocytes
Characteristic Immunophenotyping (CD 19, 20, 23) & CD5 positive (not supposed to be there)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Epidemiology of CLL

A

> 1700 new cases CLL per year in the UK
Commonest leukaemia worldwide
2 males: 1 female

17
Q

Presentation of CLL

A

Often assymptomatic at presentation

Frequent findings:
Bone marrow failure (anaemia, thrombocytopenia)
Lymphadenopathy 
Splenomegaly (30%) 
Fever and sweats (B-symptoms) (< 25%)

Less common findings:
Hepatomegaly
Infections
Weight loss

18
Q

CLL associated findings

A

Immune paresis (loss of normal immunoglobulin production)

Haemolytic Anaemia

19
Q

CLL stage A

A

<3 lymph node areas

median survival is same as age matched control

20
Q

CLL stage B

A

3 or more lymph node areas

Median survival is around 8 years

21
Q

CLL stage C

A

Stage B + anaemia or thrombocytopenia

Median survival is around 6 years

22
Q

Indications for treatment of CLL

A
Progressive bone marrow failure
Massive lymphadenopathy 
Progressive splenomegaly
Lymphocyte doubling time <6 months or >50% increase over 2 months
Systemic symptoms
Autoimmune cytopenias
23
Q

Treatment of CLL

A

Often nothing – “watch and wait”

Cytotoxic chemotherapy e.g. fludarabine, bendamustine

Monoclonal antibodies e.g. Rituximab, obinutuzamab

24
Q

Poor Prognostic Markers of CLL q

A
Advanced disease (Binet stage B or C)
Atypical lymphocyte morphology
Rapid lymphocyte doubling time (<12 mth)
CD 38+ (plasma cell marker) expression
Loss/mutation p53; del 11q23 (ATM gene)
Unmutated IgVH gene status
25
Presentation of lymphoma
lymphadenopathy/hepatosplenomegaly Extranodal disease “B symptoms” bone marrow involvement
26
Assessment (staging)
Lymph node biopsy CT scan Bone marrow aspirate Trephine
27
Stage 1 lymphoma
One area of lymph node disease (usually the neck)
28
Stage 2 lymphoma
2 areas of lymph node disease both above the abdomen
29
Stage 3 Lymphoma
Above and below the abdomen
30
Stage 4 lymphoma
Extranodal disease
31
How is Non-Hodgkin Lymphoma classified
lineage (B-cell or T-cell) -Majority are B-cell in origin grade of disease (high grade or low grade) histological features of disease
32
Low grade lymphoma
Indolent, often asymptomatic responds to chemotherapy but incurable median survival varies by subtype
33
High grade lymphoma
Aggressive, fast-growing Require combination chemotherapy, steroids, antibodies (anti-CD20 monoclonal antibody + chemo) Can be cured, but again varies widely
34
Diffuse large-B cell lymphoma
Sheet of lymphoma Commonest subtype of lymphoma (of any kind) High-grade lymphoma
35
Follicular Lymphoma
2nd commonest type of lymphoma (low grade lymphoma) Looks like balls under the microscope
36
Epidemiology of Hodgkin Lymphoma
``` 30% of all lymphomas bimodal age curve: -1st peak at 15-35y -2nd peak later in life 1.9 males: 1 female ```
37
Treatment of Hodgkin Lymphoma
Combination chemotherapy (ABVD) +/- radiotherapy Use of PET scan to assess response to treatment and to limit use of radiotherapy